Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06035120 · ClinicalTrials.gov registry record · NA
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
A NA study of Emphysema or COPD and Emphysema, Pulmonary, sponsored by Pulmonx Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06035120 is a NA study of Emphysema or COPD and Emphysema, Pulmonary that is actively recruiting participants, run by Pulmonx Corporation. The registered enrollment target is 200 participants, above the 46-participant average among 7 other Emphysema or COPD trials with a reported enrollment target (335% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06035120, a NA study of Emphysema or COPD and Emphysema, Pulmonary, is actively recruiting participants, sponsored by Pulmonx Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.
Conditions Studied
Interventions
- DEVICE AeriSeal System
Study Locations (20)
Pennsylvania
- Penn Medicine - Philadelphia
- Temple University - Philadelphia
- Allegheny General Hospital - Pittsburgh
- University of Pittsburgh Medical Center (UPMC) - Pittsburgh
Illinois
- Northwestern University - Chicago
- University of Chicago Medical Center - Chicago
- OSF Saint Francis Medical Center - Peoria
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Brigham Lung Center - Boston
Australia
- Royal Adelaide Hospital - Adelaide
- Wesley Hospital - Brisbane
Arizona
- Banner University Medical Center - Phoenix
Connecticut
- Saint Francis Hospital and Medical Center (Trinity Health of New England) - Hartford
Florida
- Orlando Health - Orlando
Michigan
- Henry Ford Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06035120
The ClinicalTrials.gov registry entry for NCT06035120 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 46-participant average among 7 other Emphysema or COPD trials with a reported enrollment target (335% higher). The listed sponsor is Pulmonx Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Emphysema or COPD appearing as the primary indexed condition, and to 1 intervention - of which AeriSeal System is the first listed.
NCT06035120 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Pennsylvania, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06035120 about?
NCT06035120 is a clinical study titled "An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema". This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Charti...
What is the current status of trial NCT06035120?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-02-22. Estimated completion is 2028-03-31.
What conditions does trial NCT06035120 study?
This clinical trial studies the following conditions: Emphysema or COPD, Emphysema, Pulmonary.
What interventions are being tested in trial NCT06035120?
The interventions under investigation include: AeriSeal System (DEVICE).
Who is sponsoring clinical trial NCT06035120?
This trial is sponsored by Pulmonx Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06035120 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Emphysema or COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
-
Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction
RECRUITING · NA
-
Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema
RECRUITING · NA
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
-
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RECRUITING · Phase 1
-
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.